Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a report issued on Wednesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Up 3.4 %

Shares of EVOK opened at $4.31 on Wednesday. The firm has a market cap of $6.40 million, a PE ratio of -0.39 and a beta of 0.15. The company’s fifty day moving average is $4.60 and its two-hundred day moving average is $5.07. Evoke Pharma has a fifty-two week low of $3.54 and a fifty-two week high of $12.32.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. acquired a new position in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned 1.42% of Evoke Pharma as of its most recent SEC filing.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.